A United States health-sector stock is described as up almost 70 percent amid early cancer-detection news.

Coverage cited in the article names Grail and its Galleri multi-cancer blood test.

A prospective study of that blood test identified seventeen distinct cancers, the article says.

A separate cited line says Grail shares rose 180 percent in six months, unlike the almost 70 percent opening claim.

Federal regulators are reviewing submissions, and advisory panels are looking at how well and how safely the test works.

The article says these multi-cancer blood tests could reach the public as early as next year if regulators clear them.

It says early detection is being discussed as a factor in survival, and funding is moving into diagnostic companies.

Read the full story on the multi-cancer blood test and the stock move described in the article.